TabletsClinical Overview
Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally after meals with water to avoid gastric irritation. For motion sickness, take 2 hours before travel. Complete prescribed duration.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence, sedation, weight gain, nausea, dyspepsia, headache. Rare/Severe: Cinnarizine-induced parkinsonism (tremor, rigidity, bradykinesia, especially in elderly patients with prolonged use), depression, and cholestatic jaundice.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Avoid prolonged administration in elderly patients due to high risk of irreversible or prolonged drug-induced parkinsonism and tardive dyskinesia. Contraindicated in Parkinson's disease. May cause significant drowsiness; avoid alcohol.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Cinnarizine Tablets 25mg
Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.
Cinnarizine 20mg + Dimenhydrinate 40mg Tablets
Cinnarizine and Dimenhydrinate is a dual-target vestibular formulation. Cinnarizine acts as a selective T-type calcium channel blocker, inhibiting calcium influx into vestibular sensory hair cells and dampening labyrinthine hyper-reactivity, while dimenhydrinate (diphenhydramine-theoclate salt) blocks H1 receptors in the vestibular nuclei and solitary tract, suppressing the vegetative emetic reflex. Together, they provide synergistic peripheral and central vestibular suppression. Indicated for the symptomatic treatment of various origins of vertigo in adults.
Cinnarizine 20mg + Domperidone 15mg Tablet
Cinnarizine (20mg) and Domperidone (15mg) Tablets is a dual-action vestibular sedative and antiemetic combination. Cinnarizine acts as a selective T-type voltage-gated calcium channel blocker and H1-antihistamine, suppressing labyrinthine overstimulation in the inner ear. Domperidone blocks peripheral dopamine D2 receptors in the CTZ, preventing motion-induced and labyrinthine nausea. Indicated for vertigo, motion sickness, Meniere's disease, and peripheral vestibular disorders accompanied by nausea and vomiting.